Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

Keytruda's first approval by US FDA came in the year 2014 for advanced skin cancer. Now, the immunotherapy drug is being used ...

Keytruda, an immunotherapy drug, is transforming cancer treatment in India by helping the immune system fight cancer cells. Experts say it offers improved outcomes in several advanced cancers and ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

A game changer in cancer treatment, Keytruda, works by harnessing the body’s immune system to attack cancer cells. While its ...

The Cancer Calculus, coordinated by the International Consortium of Investigative Journalists with Deutsche Welle and 46 media partners, brought together 124 journalists in 37 countries. Drawing on ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) The ...

Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior sys ...

Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...

Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.